But we have also shown that the interaction of melanoma-expressed CD70 with the MAPK pathway does not interfere with the inhibitory activities of PLX-4032 (Vemurafenib) in melanoma cells on MAPK pathway activation and melanoma cell survival. Here, CD70 is linked to melanoma.